Generic placeholder image

Current Pharmaceutical Analysis


ISSN (Print): 1573-4129
ISSN (Online): 1875-676X

Research Article

Analysis of Shenhuang Capsule using HPLC: Method Development, Validation, and Application

Author(s): Yuankai Si*, Zhigui Wu, Gu Li, Hua Li, Pei Ge, Huan Liu, Wenqiang Zhang, Yanli Xu, Yuanqiong Huang* and Meijuan Chen*

Volume 18, Issue 7, 2022

Published on: 14 June, 2022

Page: [704 - 709] Pages: 6

DOI: 10.2174/1573412918666220427135241

Price: $65


Objective: Shenhuang (SH) capsule is a traditional Chinese medicine compound preparation containing rhubarb, coptis, scutellaria, salvia and Pueraria, used for diabetic nephropathy studied by our research group in the early stage. This study aims to develop the method of qualitative identification and content determination of the main active ingredients of SH capsules so as to establish the quality standard.

Methods: HPLC method was used to determine the contents of rhein, Pueraria, and tanshinone in SH capsules. The determination method of SH capsules was established through the determination of specificity, regression equation, precision, repeatability, and recovery. The general quality standard of SH capsules was established by measuring water content, disintegration time, and microorganism. The contents of rhein, puerarin, and tanshinone IIA in SH capsules were determined by HPLC.

Results: The precision was 1.10–3.00% and the reproducibility and recovery rates were 95.0– 105.7%. The moisture determination, disintegration time, and microorganism examination of SH capsule were all in line with the standard.

Conclusion: The stable, feasible, simple, and reliable content determination method was established through the content determination of SH capsules and the general quality standard test.

Keywords: Shenhuang capsule, HPLC, method development, rhein, puerarin, tanshinone Ⅱ A.

Graphical Abstract
Wei, X.; Tao, J.; Shen, Y.; Xiao, S.; Jiang, S.; Shang, E.; Zhu, Z.; Qian, D.; Duan, J. Sanhuang Xiexin Tang ameliorates type 2 diabetic rats via modulation of the metabolic profiles and NF-κB/PI-3K/Akt signaling pathways. Front. Pharmacol., 2018, 9, 955.
[] [PMID: 30210342]
Zhong, Y.; Lee, K.; Deng, Y.; Ma, Y.; Chen, Y.; Li, X.; Wei, C.; Yang, S.; Wang, T.; Wong, N.J.; Muwonge, A.N.; Azeloglu, E.U.; Zhang, W.; Das, B.; He, J.C.; Liu, R. Arctigenin attenuates diabetic kidney disease through the activation of PP2A in podocytes. Nat. Commun., 2019, 10(1), 4523.
[] [PMID: 31586053]
ElGamal, H.; Munusamy, S. Aldose reductase as a drug target for treatment of diabetic nephropathy: Promises and challenges. Protein Pept. Lett., 2017, 24(1), 71-77.
[PMID: 27894247]
Grewal, A.S.; Thapa, K.; Kanojia, N.; Sharma, N.; Singh, S. Natural compounds as source of Aldose Reductase (AR) inhibitors for the treatment of diabetic complications: A mini review. Curr. Drug Metab., 2020, 21(14), 1091-1116.
[] [PMID: 33069193]
Kumar, M.; Kasala, E.R.; Bodduluru, L.N.; Dahiya, V.; Lahkar, M. Baicalein protects isoproterenol induced myocardial ischemic injury in male Wistar rats by mitigating oxidative stress and inflammation. Inflamm. Res., 2016, 65(8), 613-622.
[] [PMID: 27071824]
Pathomthongtaweechai, N.; Chutipongtanate, S. AGE/RAGE signaling-mediated endoplasmic reticulum stress and future prospects in non-coding RNA therapeutics for diabetic nephropathy. Biomed. Pharmacother., 2020, 131, 110655.
[] [PMID: 32853909]
Rabbani, N.; Thornalley, P.J. Advanced glycation end products in the pathogenesis of chronic kidney disease. Kidney Int., 2018, 93(4), 803-813.
[] [PMID: 29477239]
Zhuang, A.; Forbes, J.M. Diabetic kidney disease: A role for advanced glycation end-product receptor 1 (AGE-R1)? Glycoconj. J., 2016, 33(4), 645-652.
[] [PMID: 27270766]
Liu, Y.W.; Hao, Y.C.; Chen, Y.J.; Yin, S.Y.; Zhang, M.Y.; Kong, L.; Wang, T.Y. Protective effects of sarsasapogenin against early stage of diabetic nephropathy in rats. Phytother. Res., 2018, 32(8), 1574-1582.
[] [PMID: 29682805]
Sanajou, D.; Ghorbani Haghjo, A.; Argani, H.; Aslani, S. AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions. Eur. J. Pharmacol., 2018, 833, 158-164.
[] [PMID: 29883668]
Zhou, X.; Liu, Z.; Ying, K.; Wang, H.; Liu, P.; Ji, X.; Chi, T.; Zou, L.; Wang, S.; He, Z. WJ-39, an aldose reductase inhibitor, ameliorates renal lesions in diabetic nephropathy by activating Nrf2 signaling. Oxid. Med. Cell. Longev., 2020, 2020, 7950457.
[] [PMID: 32566101]
Cao, Y.; Chang, S.; Dong, J.; Zhu, S.; Zheng, X.; Li, J.; Long, R.; Zhou, Y.; Cui, J.; Zhang, Y. Emodin ameliorates high-fat-diet induced insulin resistance in rats by reducing lipid accumulation in skeletal muscle. Eur. J. Pharmacol., 2016, 780, 194-201.
[] [PMID: 27020550]
Paul, M.; Hemshekhar, M.; Kemparaju, K.; Girish, K.S. Berberine mitigates high glucose-potentiated platelet aggregation and apoptosis by modulating aldose reductase and NADPH oxidase activity. Free Radic. Biol. Med., 2019, 130, 196-205.
[] [PMID: 30391673]
Qiu, Y.Y.; Tang, L.Q.; Wei, W. Berberine exerts renoprotective effects by regulating the AGEs-RAGE signaling pathway in mesangial cells during diabetic nephropathy. Mol. Cell. Endocrinol., 2017, 443, 89-105.
[] [PMID: 28087385]
Han, Q.T.; Ren, Y.; Li, G.S.; Xiang, K.L.; Dai, S.J. Flavonoid alkaloids from Scutellaria moniliorrhiza with anti-inflammatory activities and inhibitory activities against aldose reductase. Phytochemistry, 2018, 152, 91-96.
[] [PMID: 29758522]
Kumar Pasupulati, A.; Chitra, P.S.; Reddy, G.B. Advanced glycation end products mediated cellular and molecular events in the pathology of diabetic nephropathy. Biomol. Concepts, 2016, 7(5-6), 293-309.
[] [PMID: 27816946]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy